Alzheimer's disease stage is tracked by biomarkers

Researchers say that repeated tests could be used to help improve early detection rate and treatment.

Tests could predict onset of Alzhemier's before symptoms appear
Tests could predict onset of Alzhemier's before symptoms appear

Four biomarkers for Alzheimer's disease could help identify how far the condition has progressed in particular patients, research suggests.

Dr Raymond Lo of the University of California, Berkeley, and his team showed amyloid deposition in the brain occurs early and before other degradation, such as atrophy.

A range of biomarker tests to detect the disease were shown to be sensitive at different stages of progression.

The findings suggest that repeated biomarker tests could predict the onset of the disease before symptoms first appear.

Early detection could help make treatment more effective, but studies have not yet explored whether tests developed to detect the disease are specific to different stages. At present, the only way to confirm the progression of Alzheimer's disease is at postmortem.

Dr Lo and colleagues examined 819 people aged 55-90 years with normal cognition, mild cognitive impairment or Alzheimer's disease.

Over three years, the researchers measured beta-amyloid 42 levels, fluorodeoxyglucose F18 (FDG) uptake, hippocampal volume and Alzheimer Disease's Assessment Scale-cognitive subscale score.

They found rates of change in beta-amyloid 42 did not differ across stages of the disease. But changes in glucose metabolism and hippocampal volume accelerated as cognitive function deteriorated.

The researchers said the finding implied that beta-amyloid 42 level in CSF declines before the onset of cognitive impairment.

However, measures of neuronal function and injury, such as glucose metabolism and hippocampal atrophy, change with disease stage.

The researchers concluded that the patterns of biomarkers 'capture Alzheimer's disease pathological states sequentially and that their predictive values for cognitive decline depend on the stage of the disease'.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

BMA GP chair: 'GPs let down by tone deaf NHS demands on face-to-face appointments'

BMA GP chair: 'GPs let down by tone deaf NHS demands on face-to-face appointments'

NHS England has let down general practice with its 'tone deaf' demand for all patients...

GPs told to offer face-to-face appointments for all patients

GPs told to offer face-to-face appointments for all patients

GPs have condemned a 'blanket' demand from NHS England that all patients should be...

GP federation network seeks to boost primary care representation amid NHS reforms

GP federation network seeks to boost primary care representation amid NHS reforms

The NHS Confederation has set up a national network for GP federations in a bid to...

Sharp rise in GPs seeking mental health support during past year

Sharp rise in GPs seeking mental health support during past year

The number of GPs seeking help from NHS Practitioner Health, the specialist service...

Podcast: The GP workload crisis, mental wellbeing and vaccination success

Podcast: The GP workload crisis, mental wellbeing and vaccination success

In this episode of our new podcast Talking General Practice we look at the GP workload...

Long wait for COVID-19 public inquiry 'could drive doctors to quit NHS'

Long wait for COVID-19 public inquiry 'could drive doctors to quit NHS'

Doctors' leaders have criticised government plans to delay a public inquiry into...